Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
76.91B
Market cap76.91B
Price-Earnings ratio
18.17
Price-Earnings ratio18.17
Dividend yield
0.46%
Dividend yield0.46%
Average volume
906.42K
Average volume906.42K
High today
$749.09
High today$749.09
Low today
$731.37
Low today$731.37
Open price
$749.09
Open price$749.09
Volume
339.46K
Volume339.46K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $731.80, giving the company a market capitalization of 76.91B. It carries a P/E multiple of 18.17 and pays a dividend yield of 46.4%.

On 2026-01-16, Regeneron(REGN) stock moved within a range of $731.37 to $749.09. With shares now at $731.80, the stock is trading +0.1% above its intraday low and -2.3% below the session's peak.

Trading activity shows a volume of 339.46K, compared to an average daily volume of 906.42K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

TipRanks 1d
Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview Regeneron Pharmaceuticals...

TipRanks 2d
Regeneron Ends Phase 2 Heart Failure Trial for REGN5381: What Investors Should Know

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful i...

Nasdaq 3d
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

AbbVie ABBV announced that it has signed an agreement with the Trump administration to lower drug prices in the United States. Under the agreement, AbbVie has...

ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More REGN News

Simply Wall St 4d
Assessing Regeneron Pharmaceuticals Valuation After Recent Analyst Buy Upgrades

Advertisement Analyst upgrades and what they might mean for REGN Regeneron Pharmaceuticals (REGN) has come into focus after multiple analysts, including Bank...

Assessing Regeneron Pharmaceuticals Valuation After Recent Analyst Buy Upgrades

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .